Targeting the NTSR2/TrkB oncogenic pathway in chronic lymphocytic leukemia

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Current chronic lymphocytic leukemia (CLL) therapies targeting B-cell receptor or anti-apoptotic proteins show limited efficacy and resistance.
• Understanding leukemic cell survival mechanisms and identifying novel targets are crucial for improving CLL management.

Purpose of the Study:

• To investigate the therapeutic potential of the NTSR2/TRKB protein complex as a novel target in CLL.
• To develop and evaluate a peptide-based therapeutic strategy targeting the NTSR2/TRKB interaction.

Main Methods:

• Identification of the binding domain between neurotensin receptor 2 (NTSR2) and tropomyosin related kinase B (TRKB).
• Design and synthesis of a peptide targeting the TRKB binding domain.
• In vitro and ex vivo assessment of peptide efficacy on CLL cells, including signaling pathway analysis.

Main Results:

• A peptide targeting TRKB was designed, effectively reducing NTSR2/TRKB interaction.
• The peptide demonstrated internalization by CLL-B cells, impacting Src family kinase signaling and anti-apoptotic protein levels.
• Significant cytotoxic effects were observed in vitro (MEC-1 cell line) and ex vivo (30 CLL patients).

Conclusions:

• The NTSR2/TRKB protein complex represents a promising therapeutic target for CLL.
• The developed peptide shows potential for targeted therapy development in CLL, offering new treatment perspectives.